Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer - Test2 - elhamkhani - TriplyDB

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

http://www.wikidata.org/entity/Q29620902

about

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment PD-L1 expression in human cancers and its association with clinical outcomes Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer Toxicity management of immunotherapy for patients with metastatic melanoma Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting DNA damage, tumor mutational load and their impact on immune responses against cancer Harnessing the immune system to improve cancer therapy A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Targeted therapies and immunotherapy in non-small-cell lung cancer Immunotherapy for head and neck squamous cell carcinoma The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer Contemporary Treatment of Metastatic Renal Cell Carcinoma Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?New targeted treatments for non-small-cell lung cancer - role of nivolumab PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Nintedanib in NSCLC: evidence to date and place in therapy Immunotherapy for head and neck cancer: latest developments and clinical potential Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Epigenetic therapy in gastrointestinal cancer: the right combination Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far Lymphocyte-activation gene-3, an important immune checkpoint in cancer The steady progress of targeted therapies, promising advances for lung cancer Uveal melanoma as a target for immune-therapy Prime time for immune-checkpoint targeted therapy at ASCO 2015 Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer Afatinib in Non-Small Cell Lung Cancer Immunotherapy for lung cancer PD-1/PD-L1 blockades in non-small-cell lung cancer therapy Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis

P2860

Q24187274-B87A5902-CD88-4DE4-9425-CF71229CA09B Q26738359-4196D995-59CA-4085-B2EA-707FE6AA843B Q26738361-51BB098A-4C7A-448F-9189-59C2FA979115 Q26738539-6DC37DD1-A1EC-46C9-BDDD-E04A55534B70 Q26738662-CE2F0319-6437-45E9-BFBE-1B247BDA203F Q26738673-F52EACED-0887-4290-9F1C-5A587D1F7A4B Q26738685-34E45421-B1A5-470B-8F15-F2A59D6D18FE Q26738698-6B52B460-DCBA-44AC-8BE5-997F58DA2689 Q26738729-252D9C50-DD63-4D42-BDDB-196F75EB88C6 Q26738986-8C8772E1-935A-40A2-BEB4-CF1C67DE5037 Q26739850-43F574DC-4B05-4AF2-B04A-BB5F7194C49E Q26740280-433854CF-2480-405E-A2FE-50C355CBDFFD Q26740288-5E221CF0-C8F0-40E4-A4F1-CF16113BD98B Q26740594-EE14E19E-749D-4386-BF74-BBA364F46BFF Q26740601-04DCF757-9926-4D63-A9C3-B679650365E2 Q26740988-F4B49404-B042-4587-92B2-210308D20505 Q26741101-24C926E1-C8FD-45B4-A4CE-5A7AE6EAEACF Q26741998-65BEA417-CE6E-4FD0-AD1A-1CE4492D9616 Q26742047-5202555A-3379-4D43-96BC-303590AEECB2 Q26744076-37D3BC34-E1DD-4DC4-83FF-FBBBB180073B Q26744339-85C8E59D-C956-4302-9940-FE3CDE2FF495 Q26745424-0FA84FFF-BD84-4C30-B8A4-471AD09F143E Q26745428-D5B99571-BCD5-49EF-8439-C8791BB079CF Q26745516-C0E80ECA-50A2-4737-BA26-4990021A4E6A Q26745580-96C65AC2-1737-4D90-B1A7-2EA56B2EC698 Q26745590-14EAC8C1-68FB-4B30-ACA8-03448F61E542 Q26745709-4DD1A1AC-F164-4349-978E-24D42C914C4E Q26745776-EE62C778-558B-4907-9F0E-C96EC33684F0 Q26746209-021B0285-B277-4132-B51C-E1C5D92A436E Q26746895-DFBC4636-CA16-42B8-83C6-C0ADFC96053B Q26747519-DA9FC129-5050-4185-9FC2-98527F01FBD6 Q26747711-EC61F8F1-3244-4F2E-BDC8-C410326A809C Q26748851-BFFC8421-1D92-4FC4-A38F-211C3A683288 Q26749005-D20CC17B-1F46-48CA-B7A6-2B5EE7B0F8EC Q26751254-F108095C-3A37-4652-9329-A715F20CCD64 Q26765024-16FF3128-D12C-4548-8CCA-FE9A7035DF62 Q26765060-3CAF4B97-44FA-4D65-AA4E-7CA0D8F0BBD8 Q26768641-1C428C69-0571-4B78-AFDD-CE49AEB054CD Q26769713-0B9E581A-266F-48B1-8B76-8786DAA6604F Q26769728-3F6062DB-FE2E-44F5-A9D0-DCE13C2C8AE5

P2860

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

http://www.wikidata.org/entity/Q29620902

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@ast

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@en

type

label

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@ast

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@en

prefLabel

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@ast

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@en

P1433

Q29620902-76937CEF-ED27-4E8D-86A4-07F5054303B9

P1476

Q29620902-34BF4E4F-07D8-4310-A8D5-3C0078A1B015

P2093

Q29620902-002C3103-0C8D-49C2-963A-9CA14C057D3B

Q29620902-06810034-F793-4A14-BCDD-2723E18E4D78

Q29620902-0D5A3674-0F70-4E98-AD43-24BDA037279A

Q29620902-0F45BC87-180F-40AF-84F1-6F66CD33FE14

Q29620902-2EAC0D24-986B-43C0-961D-93EFB888890E

Q29620902-35308E54-311D-48E1-908F-563368DF8D3C

Q29620902-42944CA4-1405-4029-90E4-2EABAD206E34

Q29620902-4BBD0D75-1F70-4071-9A01-986516484E1D

Q29620902-4DFDFA15-1661-4606-9679-CFF7266DB20B

Q29620902-51F517A1-5FEE-48B2-987C-EC4962659415

P2860

Q29620902-043F6029-CBCC-4B49-B892-9E6ABA8BAF2A

Q29620902-04B75EC1-F9A5-4722-9B13-11A10CB854C7

Q29620902-4BD9E8DA-6BB6-45D9-9EF0-BC62FF1F3F36

Q29620902-5006AF0F-8520-4A11-B6DC-6DA44B26287F

Q29620902-60064D5F-C693-4AD8-9A73-D16913F8271B

Q29620902-793C1E17-B730-4443-8DD7-2E1F1DFEA216

Q29620902-82159B36-DC77-415F-B060-B6926D854B51

Q29620902-925676EE-4899-424E-A79B-9558832A4375

Q29620902-A793F651-0DCE-46D7-A055-55259C9ED166

Q29620902-C7931B65-28EA-4791-8E2E-897F497377BE

P304

Q29620902-6AEC0742-981B-437B-8E5E-66C054AFDEEA

P31

Q29620902-26973E8B-6AE7-429D-BB20-C0356ED25227

P3181

Q29620902-D56FA635-10BD-4C2A-B6E4-025FE46FD0CC

P356

Q29620902-E44EC026-A853-4CC6-BC4C-3DF1773E783B

P407

Q29620902-901839EE-9401-4B49-A3F9-FA54B7AC8FC8

P433

Q29620902-A202D772-9328-49BD-A3F8-246C1CA1B270

P478

Q29620902-961E976C-049F-4C51-9A9E-0D1A98CC627F

P50

Q29620902-3C011FAF-301A-4B6F-BFA2-48AAC79D1C36

Q29620902-9EE93236-D3F6-46AC-A9B0-901F1DE21C18

P577

Q29620902-6D95E2D0-B7D8-4C10-9EC0-C3B63757C071

P698

Q29620902-A34BA987-6802-45EF-A552-DDD8E0651C26

P932

Q29620902-8CA3AC02-7308-4563-BD2E-4804F6D03F59

P3181

P356

P1433

The New England Journal of Medicine

P1476

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

@en

P2093

Adam Pluzanski

http://www.w3.org/2001/XMLSchema#string

Brian Lestini

http://www.w3.org/2001/XMLSchema#string

Christine Baudelet

http://www.w3.org/2001/XMLSchema#string

Christopher T Harbison

http://www.w3.org/2001/XMLSchema#string

David R Spigel

http://www.w3.org/2001/XMLSchema#string

David Waterhouse

http://www.w3.org/2001/XMLSchema#string

Elena Poddubskaya

http://www.w3.org/2001/XMLSchema#string

Esther Holgado

http://www.w3.org/2001/XMLSchema#string

Everett E Vokes

http://www.w3.org/2001/XMLSchema#string

Joachim G Aerts

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Programmed death ligand-1 expression in non-small cell lung cancer.

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

P304

123-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8446

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1504627

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Karen L. Reckamp

Marina Garassino

P577

2015-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26028407

http://www.w3.org/2001/XMLSchema#string

P932

4681400

http://www.w3.org/2001/XMLSchema#string